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Introduction and objectives: Tendinopathy, which is accompanied by structural changes 
to the tendon, is a common sporting injury. The aim of this study was to evaluate the 
efficacy and safety of a nutritional supplement containing mucopolysaccharides, type i 
collagen and vitamin C (TendoactiveTM) on the clinical and structural evolution of 
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Introduction
Tendon damage arising due to overload or a tendinopathy is 
a condition which is accompanied by pain and results in 
joint dysfunction and reduced exercise tolerance. Indeed, 
this common sports-related condition is estimated to 
account for 30-50% of sporting injuries1. For example, it is 
known to affect up to 30% of runners, with the Achilles 
tendon being the most commonly affected (56.6%)2. 
Similarly, around 40% of athletes involved in racket sports 
Eficacia y seguridad de un tratamiento oral a base de mucopolisacáridos, colágeno 
tipo i y vitamina C en pacientes con tendinopatías
Resumen 
Introducción y objetivos: La tendinopatía es una lesión frecuente durante la práctica 
deportiva que cursa con una alteración estructural del tendón. El objetivo de este 
estudio fue evaluar la eficacia y la seguridad de un complemento alimentario a base de 
mucopolisacáridos, colágeno tipo i y vitamina C (Tendoactive®) sobre la evolución clínica 
y estructural de las tendinopatías del tendón de Aquiles, rotuliano y del epicóndilo 
lateral del codo.
Material y métodos: Se realizó un estudio multicéntrico prospectivo, de tipo exploratorio 
en fase iv, abierto y no comparativo. Se incluyeron un total de 98 pacientes con 
tendinopatías (32 de Aquiles, 32 de rotuliano y 34 del epicóndilo lateral) que recibieron 
una dosis diaria de 435 mg de mucopolisacáridos, 75 mg de colágeno tipo i y 60 mg de 
vitamina C (equivalente a 3 cápsulas al día de Tendoactive®) durante 90 días consecutivos. 
Mensualmente se evaluó el dolor en reposo y en actividad mediante una escala visual 
analógica (EVA), la función articular mediante los cuestionarios VISA-A, VISA-P y PRTEE, 
y se caracterizó ecográficamente el tendón afectado.
Resultados: En los 3 tipos de tendinopatía se registró una reducción significativa del 
dolor tanto en reposo como en actividad desde la primera visita de control (día 30) hasta 
el final del estudio (día 90). Asimismo, el día 90 se detectó una mejora del 38% en 
VISA-A, del 46% en VISA-P y del 77% en PRTEE (p < 0,001). Simultáneamente se registró 
una reducción del 12% en el grosor del tendón de Aquiles, del 10% en el rotuliano y del 
20% en el tendón del epicóndilo lateral (p < 0,05).
Conclusiones: Los resultados del estudio indican que la administración de Tendoactive® 
es segura y eficaz para mejorar los síntomas clínicos y la evolución estructural de las 
tendinopatías del tendón de Aquiles, tendón rotuliano y tendón del epicóndilo lateral.
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tendinopathies of the Achilles tendon, patellar tendon and lateral epicondyle tendon in 
the elbow.
Materials and methods: A multicenter, open-label, non-comparative, prospective, 
exploratory phase iv study was performed. A total of 98 tendinopathy patients (32 
Achilles, 32 patellar and 34 lateral epicondylar), who received a daily dose of 435 mg 
mucopolysaccharides, 75 mg type i collagen and 60 mg vitamin C (equivalent to three 
capsules of TendoactiveTM per day) for 90 consecutive days, were included. Every month, 
pain at rest and when active was assessed using a visual analogue scale (VAS), joint 
function was assessed using the VISA-A, VISA-P and PRTEE questionnaires, and the tendon 
affected was characterized by ultrasound.
Results: A significant reduction in pain both at rest and when active was observed 
between the first control visit (day 30) and the end of the study (day 90) for all three 
types of tendinopathy. Thus, a 38% improvement in VISA-A, 46% in VISA-P and 77% in 
PRTEE was observed on day 90 (P < .001). Similarly, a 12% decrease in the thickness of 
the Achilles tendon, a 10% decrease in the patellar tendon and a 20% decrease in the 
lateral epicondyle tendon was observed (P < .05). 
Conclusions: The results of this study show that the administration of TendoactiveTM is 
safe and effective for improving the clinical symptoms and structural evolution of 
tendinopathies of the Achilles, patella and lateral epicondyle tendons.
© 2013 Consell Català de l’Esport. Generalitat de Catalunya. Published by Elsevier 
España, S.L. All rights reserved.
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present tendinopathy of the lateral epicondyle tendon 
(tennis elbow) at some point in their career3. Although the 
term tendinitis has historically been used, histological 
studies have shown that the affected tendon is essentially 
free from inflammation4. In contrast, tendinopathy is 
characterized by a degeneration of the extracellular 
matrix, with a structural disorganization of the collagen 
fibers and neovascularisation5.
Traditional therapeutic strategies based on the use of 
anti-inflammatories have been found to be ineffective at 
correcting the evolution of this condition. Although 
numerous therapeutic alternatives for treating tendon 
disorders are known, the majority are considered to lack a 
scientific basis6,7, the main exception to this being eccentric 
exercises, which are particularly useful for treating chronic, 
non-insertional Achilles tendinopathy8. In light of the 
above, the present study evaluates the therapeutic efficacy 
of a nutritional supplement (TendoactiveTM) containing 
mucopolysaccharides, type i collagen and vitamin C. In 
vitro studies in tendinopathy models have shown the 
potential of this supplement for correcting structural 
alterations in the extracellular matrix of the tendon9.
Materials and methods
A multicenter, open-label, non-comparative, prospective, 
exploratory phase iv study was performed to study the 
efficacy of TendoactiveTM (Bioiberica S.A., Palafolls, Spain) 
for treating patients with clinically and ultrasound-
diagnosed diagnosis tendinopathy. The study was performed 
in accordance with national and international guidelines 
concerning research in human subjects, such as the 
Declaration of Helsinki. All participants provided written 
informed consent for their participation and the protocol 
was approved by the ethics committee from the Consell 
Català de l’Esport (Generalitat de Catalunya).
A total of 98 patients of both sexes aged 18 years or older 
were included (32 with Achilles tendinopathy, 32 with 
patellar tendinopathy and 34 with lateral epicondyle 
tendinopathy, or tennis elbow). The diagnosis of 
tendinopathy was based on a clinical examination, with 
swelling of the tendon that was painful upon palpation, and 
confirmed by ultrasound as local swelling of the tendon, an 
irregular structure with hypoechoic regions and irregular 
orientation of the fibers. Patients with clinically suspected 
systemic disease (spondyloarthropathy, gout, hyperlipidemia, 
rheumatoid arthritis, sarcoidosis) or a neurological disorder 
were excluded. Pregnant women were also excluded. As 
this was a pilot exploratory study, the sample size was 
determined using publications concerning similar studies as 
reference10,11.
All patients included in the study took 3 capsules of 
TendoactiveTM (435 mg mucopolysaccharides, 75 mg type i 
collagen and 60 mg vitamin C) per day for 90 consecutive 
days. Patients were followed-up monthly, with visits at days 
30, 60 and 90 after commencement of treatment. The day 
prior to commencement of treatment (day 0) was established 
as the baseline visit.
Joint function was assessed at each visit using the 
validated Victorian Institute of Sport Assessment 
questionnaire specific for the Achilles (VISA-A)12 or patellar 
tendon (VISA-P)13. The validated Patient-rated Tennis Elbow 
Evaluation (PRTEE)14 questionnaire was used to assess 
elbow function. Pain intensity was determined at rest and 
when active using a 10-centimetre visual analogue scale 
(VAS). At each visit the tendon was characterized by 
ultrasound, including measuring the bilateral cross-sectional 
thickness of the two Achilles tendons at the point of 
maximum swelling, and the type of tendinopathy, degree 
of effacement of the paratenon, degree of heteroechogenicity, 
hypoechogenicity, neovascularization and the presence of 
isolated intratendinous ruptures was determined. 
Analgesic consumption and the appearance of any 
adverse effect were recorded throughout the experimental 
period. Patient satisfaction with the treatment was assessed 
at each visit using a subjective assessment question.
All data obtained were subjected to a descriptive 
statistical analysis. A repeated measures analysis, with 
time as an inter-individual factor, was performed using the 
TOEP-type MIXED model in the Statistical Analysis System 
software package (version 6.11; SAS Institute, Cary, NC, 
USA) to evaluate the efficacy throughout the experimental 
period. The LS-MEANS test was used to compare means. 
Categorical variables were analyzed using the Wilcoxon 
test. Statistical significance was established at a = .05.
Results
A total of 98 patients complied with the inclusion criteria 
and agreed to participate in the study. These patients were 
recruited from the 17 participating medical centers between 
September 2012 and January 2013. As 28 patients did not 
complete the entire follow-up period, a total of 70 patients 
complied with the established protocol. The mean age of 
the participants was 49.2 ± 3.64 years for the Achilles 
tendinopathy group (AC group), 47.7 ± 1.69 years for the 
patellar tendinopathy group (PA group) and 39.0 ± 2.44 
years for the lateral epicondyle tendinopathy group (LE 
group). Similarly, the BMI was 24.1 ± .73, 25.6 ± .75 and 
23.1 ± .65 kg/m2 for the AC, PA and LE groups, 
respectively.
A significant reduction in the pain experienced at rest 
(Figure 1) and when active (Figure 2) was observed for all 
three groups. This reduction was progressive throughout 
the study, and was significant at the first control visit 
performed on day 30 of treatment (P < .01). At the end of 
the study (day 90), the intensity of the pain at rest had 
decreased by 80% for the AC group, 71% for the PA group 
and 91% for the LE group with respect to baseline pain 
(P < .001), whereas pain when moving was reduced by 82% 
for the AC group, 73% for the PA group and 81% for the LE 
group (P < .001). 
The functional questionnaires showed a linear 
improvement throughout the study (Figure 3). In 
agreement with the reduction in pain intensity, the 
functional improvement for all groups was significant 
from the first visit (P < .001). With respect to the 
baseline situation, the improvement recorded at the end 
of the study was 38%, 46% and 77% for the AC, PA and LE 
groups, respectively (P < .001). 
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A significant reduction in the thickness of the affected 
tendon was observed for all three patient groups (Figure 4). 
This reduction was 12% for the AC group, 10% for the PA 
group and 20% for the LE group (P < .05). The reduction for 
the AC and PA groups occurred between the baseline visit 
and second follow-up visit (day 60) and thereafter remained 
constant until the end of the study, whereas the reduction 
for the LE group was progressive from the onset of the 
study. Other ultrasound parameters also showed a structural 
improvement in the affected tendon for all patient groups 
(Table 1). The decrease in hypoechogenicity was significant 
for the AC and LE groups, and tended to significance for the 
PA group, whereas the degree of neovascularization only 
decreased in patients with tennis elbow. The degree of 
heteroechogenicity and effacement of the paratenon 
improved for the AC and LE groups, and to a lesser extent 
for the PA group, in which only a numerical improvement 
was detected.
Figure 1 Evolution of pain intensity at rest (VAS) with time.
* P < .05 with respect to the baseline visit.
Figure 2 Evolution of pain intensity when active (VAS) with time.
* P < .05 with respect to the baseline visit.
Figure 3 Evolution of the joint function scales VISA-A, VISA-P and PRTEE in patients with tendinopathy of the Achilles tendon, patellar 
tendon or lateral epicondylar tendon with time.
* P < .05 with respect to the baseline visit.
Figure 4 Evolution of the thickness of the affected tendon with time.
* P < .05 with respect to the baseline visit.
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Table 1 Ultrasound characterization of the affected tendon before and after treatment
 Effacement of Heteroechogenicity Hypoechogenicity Neovascularisation 
 the paratenon
Degree Baseline End  P Baseline  End  P  Baseline  End  P  Baseline  End  P  
of (d0) (d90)  valueb (d0)  (d90)  value (d0)  (d90)  value (d0)  (d90)  value 
severity (%)a (%)  (%) (%)  (%) (%)  (%) (%) 
AC Group
 0 33 94 < .0001 28 71 .0012 21 75 .0015 35 63 NS
 1 39 6  33 29  37 19  40 13 
 2 22 0  33 0  42 6  25 25 
 3 6 0  6 0  0 0  0 0 
PA Group
 0 42 64 NS 15 38 NS 28 60 .0737 40 33 NS
 1 42 29  55 46  17 20  25 33 
 2 16 0  10 0  39 20  15 27 
 3 0 7  20 15  17 0  20 7 
LE Group
 0 40 79 .0231 17 53 .0035 15 63 < .0001 26 74 < .0001
 1 48 21  46 42  15 26  37 26 
 2 8 0  25 0  31 5  19 0 
 3 4 0  13 5  38 5  19 0  
NS: not significant.
a Percentage distribution of the patients on the severity scales for each of the ultrasound evaluation parameters.
b P value for the comparison of the percentage distribution of patients before and after treatment.
NSAID consumption decreased significantly during the 
study. Thus, for the AC group, the percentage of patients 
who had taken at least one dose of NSAID 30 days prior to 
the baseline visit was 28%, whereas this percentage 
decreased to 5% in the 30 days prior to the final visit 
(P < .05). The reduction was also significant for patients in 
the PA group (from 43% to 14%; P < .05), but was only 
numerical for the LE group (from 29% to 15%; P > .05).
The percentage of patients who evaluated the treatment 
received positively or very positively in the subjective 
acceptance questionnaire was 95% for the AC group, 90% 
for the PA group and 85% for the LE group. None of the 
patients evaluated the treatment negatively. As far as 
safety is concerned, no adverse effects were reported 
during the study.
Discussion
The aim of this study was to evaluate the efficacy and safety 
of a nutritional supplement containing mucopolysaccharides, 
type i collagen and vitamin C (TendoactiveTM) on the clinical 
and structural evolution of tendinopathies. To this end, an 
open-label multicenter study was designed in order to study 
a relevant population of patients. The results obtained 
showed a significant improvement in the three types of 
tendinopathy included in this study. It should be noted that 
the three tendons studied (Achilles, patellar and lateral 
epicondylar) have distinctive characteristics, such as the 
paratenon or type of blood supply, thus meaning that they 
can be considered to represent anatomical variations of the 
various tendons present in the body. In light of this, the 
results obtained in this study could be applicable to the 
majority of tendons.  Validated functional questionnaires 
(VISA-A, VISA-P, PRTEE) and a visual analog pain scale (VAS) 
were used to evaluate the improvements observed.
The results obtained are consistent with an initial 
observational-type pilot study in which treatment with 
TendoactiveTM produced a 69% pain reduction in patients 
with Achilles tendinopathy, 83% in patients with tennis 
elbow and 75% in patients with supraspinous tendinopa-
thy15. The pain reduction obtained in the present study 
after treating Achilles patients for 12 weeks (80%) is 
equivalent to that described using other therapeutic 
strategies, such as eccentric exercises. In other studies, 
pain reductions of between 60%11 and 84%10 have been 
obtained in those tendons that respond to treatment 
after 12 weeks. 
In the case of patellar tendinopathy, reductions of 31% 
in pain intensity and functional improvements of 67% in 
VISA-P have been obtained at 12 weeks after an intervention 
with PRP and a physical therapy programme16. Treatment 
TendoactiveTM resulted in a pain reduction of 71% and an 
improvement in the VISA-P test of 46%, although these 
values may be affected by the fact that all ultrasound-
confirmed patellar tendinopathies were included in this 
study, whereas only patients with degenerative 
tendinopathy and clinical symptoms lasting for more than 
12 months were included in the PRP and physical therapy 
study.
In studies involving lateral epicondylalgia patients, pain 
reductions of 81% have been reported when using an 
eccentric exercise protocol17, whereas pain reduction in 
the present study was 91%.
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Although they have been associated with some degree of 
subjectivity, pain scales and functional questionnaires are 
valid and useful tools for clinically assessing tendinopathies. 
In contrast, ultrasound characterization parameters are 
purely objective and allow the structural evolution of the 
tendon to be analyzed. It is significant that the clinical 
improvements observed in the three types of tendinopathy 
studied are associated with structural improvements such 
as a reduced thickness of the affected tendon, or a lesser 
degree of neovascularization in the LE group. Similar 
associations have been described in other studies. This, in 
2010, Humphrey et al.18 published a study in which a 
clinical improvement of 82% in the VISA-A scale was 
associated with a 13% reduction in tendon thickness and 
reduced neovascularization in patients with non-insertional 
Achilles tendinopathy treated with high-volume ultrasound-
guided injections. 
Although the mechanism by which TendoactiveTM exerts 
its effect is not fully understood, in vitro9 studies have 
shown that it helps to restore the equilibrium in the 
extracellular matrix of the tendon, stimulates type i 
collagen synthesis and counteracts the catabolic mechanisms 
in tenocytes undergoing a degenerative process, thereby 
increasing their proliferation and cell activity.
This study provides evidence regarding the efficacy of 
TendoactiveTM for the treatment of tendinopathies. The 
strong points of this study are the use of a sufficient 
number of patients and the ultrasound-based follow-up of 
the affected tendons. The main weakness of this study is 
the lack of a control group that can be used to compare the 
evolution of the patients. However, both the clinical and 
ultrasound findings are significant and consistent, and 
suggest the need for a controlled, randomized study.
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